<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Road</title>
	<atom:link href="http://www.tapanray.in/tag/road/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Patent Expiry No Longer End of The Road</title>
		<link>http://www.tapanray.in/patent-expiry-no-longer-end-of-the-road/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patent-expiry-no-longer-end-of-the-road</link>
		<comments>http://www.tapanray.in/patent-expiry-no-longer-end-of-the-road/#comments</comments>
		<pubDate>Sun, 03 Dec 2017 23:30:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Adalimumab]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[end]]></category>
		<category><![CDATA[exemptia]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Infliximab]]></category>
		<category><![CDATA[labyrinth]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[MabThera]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Remicade]]></category>
		<category><![CDATA[Rituxan]]></category>
		<category><![CDATA[Rituximab]]></category>
		<category><![CDATA[Road]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8600</guid>
		<description><![CDATA[Who says that the phenomenal success of blockbuster drugs is mostly eaten away by  ‘look-alikes’ of the same, immediately after respective patent expiry? It doesn’t seem to be so any longer, not anymore! Several examples will vindicate this emerging trend. &#8230; <a href="http://www.tapanray.in/patent-expiry-no-longer-end-of-the-road/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patent-expiry-no-longer-end-of-the-road/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Buying Physicians&#8217; Prescriptions in Cash or Kind: A Global (Dis)Order?</title>
		<link>http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder</link>
		<comments>http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/#comments</comments>
		<pubDate>Mon, 09 Sep 2013 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Academic]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[American]]></category>
		<category><![CDATA[Article]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[better]]></category>
		<category><![CDATA[Board]]></category>
		<category><![CDATA[breaking]]></category>
		<category><![CDATA[clinic]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[conflict]]></category>
		<category><![CDATA[congressional]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[do]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[educating physicians]]></category>
		<category><![CDATA[education]]></category>
		<category><![CDATA[Family]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[globally]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[gut]]></category>
		<category><![CDATA[hard]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hidden]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[induce]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[investigation]]></category>
		<category><![CDATA[journal]]></category>
		<category><![CDATA[lesser]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medical Council. of]]></category>
		<category><![CDATA[medications]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[much travelled]]></category>
		<category><![CDATA[Oregon]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[phenomenon]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[questionable]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[Road]]></category>
		<category><![CDATA[selling]]></category>
		<category><![CDATA[SG&A]]></category>
		<category><![CDATA[shun]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[unnecessary]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[wrenching]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2530</guid>
		<description><![CDATA[Recently a European business lobby reportedly raised its voice alleging pharma Multinational Corporations (MNCs) in China have been &#8216;unfairly targeted&#8217; by a string of investigations into bribery and price-fixing cases despite their generally ‘strong legal compliance’ and has suggested that China &#8230; <a href="http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biosimilar Drugs: The Roadblocks and the Road Ahead</title>
		<link>http://www.tapanray.in/biosimilar-drugs-the-roadblocks-and-the-road-ahead/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilar-drugs-the-roadblocks-and-the-road-ahead</link>
		<comments>http://www.tapanray.in/biosimilar-drugs-the-roadblocks-and-the-road-ahead/#comments</comments>
		<pubDate>Mon, 05 Sep 2011 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Ahead]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[guideloness]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[pathways]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Road]]></category>
		<category><![CDATA[Roadblocks]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=206</guid>
		<description><![CDATA[Unlike commonly used ‘small molecule’ chemical based drugs, ‘large molecule’ biologic drugs are developed from living cells and using very complex processes. These groups of drugs could range from simpler insulin to therapy for treating complex ailments like, cancer and &#8230; <a href="http://www.tapanray.in/biosimilar-drugs-the-roadblocks-and-the-road-ahead/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilar-drugs-the-roadblocks-and-the-road-ahead/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
